Innate immune responses to a single session of sprint interval training.

Sprint interval training (SIT) is a potent stimulus for physiological and metabolic adaptations comparable with those induced by traditional "aerobic" endurance training. There has been a great deal of recent research on SIT, which may lead to increased use of this type of training. The purpose of the present study was to determine the acute effects of SIT on aspects of innate immunity not previously researched in this context. Nine males completed 1 SIT and 1 resting control trial in a crossover design. Blood and saliva samples were obtained at pre-, post-, and 30 min postexercise to measure blood neutrophil oxidative burst activity (OBA) in addition to saliva secretary IgA (s-IgA) and lysozyme. SIT induced a significant depression of neutrophil fMLP-stimulated OBA (-30% for the 30-min postexercise time point, p  0.05). The main novel finding of the present study is that a single session of SIT causes significant exercise-induced immunodepression of some neutrophil functions but mucosal immunity was not depressed

Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study)

Contains fulltext : 87321.pdf (publisher's version ) (Open Access

Psoríase e o impacto na sexualidade

Psoriasis is a skin disease, not contagious, chronic, serious and considered limiting, resulting prejudice, stigma and social exclusion providing loss in quality of life.Mostly affects self-image of affected people, as well as self-esteem and self-concept.These disease characteristics bring great losses in occupational areas, damaging interpersonal relationships of individuals, which may cause impact on various occupational areas, including sexuality, which translates not only as sex itself, but also as identity, social roles, pleasure, reproduction and other. The aim of this study was to investigate the self-image of individuals with psoriasis and their influence on sexuality. This is a qualitative study of a case study with seven patients in the Reference Center, Support and Treatment Paraíba State Psoriasis installed in the clinic of the University Hospital LauroWanderley – Universidade Federal da Paraíba. Data were collected through semi-structured interview, categorized and treated according to the Content Analysis. The results show that psoriasis affects the sexuality of individuals, more significantly in women's fashion, as attribute different meanings to the body, for reasons of aesthetics and beauty.Men also feel affected, but in view of the achievement, caring companionship, and seek to clarify their partners or future partners and their relationships, about the disease. We note here the influence of culture to gender conditions.A Psoríase é uma doença dermatológica, não contagiosa, crônica, considerada grave e limitante, acarretando preconceito, estigma e exclusão social proporcionando prejuízos na qualidade de vida. Na sua grande maioria, afeta a autoimagem das pessoas acometidas, assim como a autoestima e autoconceito. Estas características da doença trazem grandes prejuízos nas áreas ocupacionais, prejudicando as relações interpessoais dos indivíduos, podendo ocasionar impacto em várias áreas ocupacionais, incluindo a sexualidade, que se traduz não só como o sexo em si, mas também como identidade, papéis sociais, prazer, reprodução entre outros. O objetivo deste estudo foi investigar sobre a autoimagem dos indivíduos com psoríase e sua influência na sexualidade. Trata-se de um estudo qualitativo do tipo estudo de caso, com sete pacientes do Centro de Referência, Apoio e Tratamento em Psoríase do Estado da Paraíba instalado no ambulatório do Hospital Universitário Lauro Wanderley – Universidade Federal da Paraíba. Os dados foram coletados por meio de entrevista semiestruturada, categorizados e tratados de acordo com a Análise de Conteúdo. Os resultados encontrados mostram que a psoríase afeta a sexualidade dos indivíduos, de forma mais significativa nas mulheres, pois atribuem significados diferentes ao corpo, por razões de estética e beleza. Os homens também se sentem afetados, mas na perspectiva da conquista, se importando com o companheirismo, e procuram esclarecer para suas companheiras ou futuras companheiras e em seus relacionamentos, sobre a doença. Observamos aqui a influência da cultura às condições de gêner

Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model

Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems biology and a first step towards computational systems medicine. The methodology introduced herein has important implications for drug development and personalized medicine

Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis

Among emerging non-albicans Candida species, Candida parapsilosis is of particular concern as a cause of nosocomial bloodstream infections in neonatal and intensive care unit patients. While fluconazole and echinocandins are considered effective treatments for such infections, recent reports of fluconazole and echinocandin resistance in C. parapsilosis indicate a growing problem. The present study describes a novel mechanism of antifungal resistance in this organism affecting susceptibility to azole and echinocandin antifungals in a clinical isolate obtained from a patient with prosthetic valve endocarditis. Transcriptome analysis indicated differential expression of several genes in the resistant isolate, including upregulation of ergosterol biosynthesis pathway genes ERG2, ERG5, ERG6, ERG11, ERG24, ERG25, and UPC2. Whole-genome sequencing revealed that the resistant isolate possessed an ERG3 mutation resulting in a G111R amino acid substitution. Sterol profiles indicated a reduction in sterol desaturase activity as a result of this mutation. Replacement of both mutant alleles in the resistant isolate with the susceptible isolate's allele restored wild-type susceptibility to all azoles and echinocandins tested. Disruption of ERG3 in the susceptible and resistant isolates resulted in a loss of sterol desaturase activity, high-level azole resistance, and an echinocandin-intermediate to -resistant phenotype. While disruption of ERG3 in C. albicans resulted in azole resistance, echinocandin MICs, while elevated, remained within the susceptible range. This work demonstrates that the G111R substitution in Erg3 is wholly responsible for the altered azole and echinocandin susceptibilities observed in this C. parapsilosis isolate and is the first report of an ERG3 mutation influencing susceptibility to the echinocandins

Rivaroxaban Compared with Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: a Randomised, Controlled, Phase 3 Trial

Background: Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. Methods: In a multicentre, parallel-group, open-label, randomised study, children (aged 0–17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≥1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed. Findings: From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87–95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29–35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11–1·41). Repeat imaging showed an improved effect of rivaroxaban on thrombotic burden as compared with standard anticoagulants (p=0·012). Major or clinically relevant non-major bleeding in participants who received ≥1 dose occurred in ten (3%) of 329 children (all non-major) receiving rivaroxaban and in three (2%) of 162 children (two major and one non-major) receiving standard anticoagulants (HR 1·58, 95% CI 0·51–6·27). Absolute and relative efficacy and safety estimates of rivaroxaban versus standard anticoagulation estimates were similar to those in rivaroxaban studies in adults. There were no treatment-related deaths. Interpretation: In children with acute venous thromboembolism, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants. Funding: Bayer AG and Janssen Research & Development. © 2020 Elsevier Ltd